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Abstract The interaction of human plasmin with human c12- 
antiplasmin was measured in the presence and absence of lyslne- 
binding ligands using the corresponding active site fluorescence 
changes. The stopped-flow method allows for direct determina- 
tion of reliable values of the second order rate constant for the 
fast association step of plasmin and c+antiplasmin in the 
absence of another interacting compound, e.g. a plasmin 
substrate. At pH 7.4,25’C, kt = 2.2 X 10’ M-l s-l was obtained. 
Substantial reductions in kl were seen in the presence of tvuns-4- 
(aminomethyl)cyclohexane-1-carhoxylic acid at concentrations 
corresponding to lysine-binding site interactions at kringle 4 of 
plasmin; at saturation the rate constant is reduced 20-fold, 
whereas the effect of saturation of kringle 1 is only a 2-fold 
reduction. It is thus found that the interaction of az-antiplasmin 
with the lysine-binding site of kringle 1 is of little importance 
compared with that of kringle 4 in regulating the inhibition 
reaction of plasmin with a*-antiplasmln. Similar results were 
recently obtained for the bovine plasmin-bovine az-antiplasmin 
reaction (Christensen et al. (1995) Biochem. J. 305, 97-102). 
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1. Introduction 
c+Antiplasmin, the primary inhibitor of plasmin (azAP), is 
present in plasma at a concentration of about 1 nM [l]. aaAP 
from two species has been characterized. Thus, the primary 
structures of human aaAP and of bovine aaAP are known [2- 
41. azAP is a member of the serpin family [5]; it has an 
acceptor site for activated coagulation factor XIII mediated 
cross-linking to fibrin during blood coagulation [6] at Gln-14 
(new numbering [3,7,8]), and contains a C-terminal extension 
with affinity to lysine-binding sites in plasmin(ogen). Purifica- 
tion of azAP is typically performed by affinity chromatogra- 
phy on immobilized plasminogen or plasminogen fragments 
containing kringle 1 [1,9]. In human azAP Lys-475 and the C- 
terminal Lys-491 appear to be involved [lo], indicating that 
the effect cannot be assigned to any single lysine-binding site 
(LBS) and therefore may involve the weak lysine-binding sites 
of plasmin(ogen) [11,12] as reported earlier [13]. In plasma, 
plasmin stems from the proenzyme plasminogen (for reviews 
see [14,15]). The primary structures of human, bovine, por- 
cine, and mouse plasminogen are highly homologous [l&21] 
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(overview [22]). The conversion of native human plasminogen 
to plasmin catalysed by plasminogen activators requires cleav- 
age of only one peptide bond (residues 561-562), but is fol- 
lowed by autocatalytic cleavage at residues 78-79 [23,24], and 
results in a disulfide-bonded two-chain plasmin molecule with 
a heavy chain (residue 79-561) containing kringles l-5 with 
the lysine-binding sites (LBS) and a light chain (residues 562- 
791) containing the catalytic serine proteinase domain. Krin- 
gles 1, 4 and 5 possess LBS [l 1,16,25-271 that mediate impor- 
tant interactions of the plasmin(ogen) and other proteins of 
the fibrinolytic system, but are not essential for the actual 
catalytic activity of plasmin. Miniplasmin, of which kringles 
14 have been removed from the proenzyme with elastase [16] 
before conversion with plasminogen activator, shows catalytic 
properties very similar to those of full-length plasmin [28], but 
its rate of association with azAP is lo-35 fold slower than 
that of full length plasmin [28,29]. Association rates, depend- 
ent on temperature and buffer composition, have been re- 
ported in the range of 7 X lo5 -2 X lo7 M-l s-l for plasmin 
and about 5 X lo5 M-l s-l for miniplasmin [2%32]. 
Eq. 1 illustrates the currently accepted reaction model for 
the inhibition of human plasmin by aZAP. It was described by 
Christensen and Clemmensen [13,30], Wiman et al. [29] and 
more recently by Longstaff and Gaffney [31]: 
E + I 2 EI’ 2 EI 1 2 (1) 
where E is the enzyme, I the inhibitor, EI* a first tight en- 
zyme-inhibitor complex and EI the final, even tighter com- 
plex. 
In previous studies of the interaction of azAP and plasmin 
conventional kinetic methods have been used to determine the 
fast association (ki) as well as the slow tightening step (kz). 
Here the kinetics of the reaction of human plasmin and CQAP 
was investigated using the stopped-flow technique to study the 
fast association by monitoring a change in intrinsic protein 
fluorescence occurring as the complex forms. The inhibition of 
the fast association reaction step by t-AMCHA (Kd = 34 uM) 
shows a hitherto overlooked importance of kringle 4 in the 
reaction of plasmin with az-antiplasmin. Little effect corre- 
sponding with interaction at the LBS of kringle 1 (& =0.4- 
1 FM) is seen. This is in accordance with recent findings in the 
bovine system [33]. 
2. Materials and methods 
2.1. Materials 
trans-4-(Aminomethyl)cyclohexane-I-carboxylic acid (t-AMCHA), 
H-n-Val-Leu-Lys-p-nitroanilide (VLKpNA) and pyro-Glu-Phe-Lys- 
p-nitroanilide (< EFKpNA) were from Chromogenix, Molndal, Swe- 
den. All other chemicals were analytic grade from either Sigma Chem- 
ical Co., St. Louis, MO, USA or Merck, Darmstadt, Germany. 
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2.2. Proteins 
Glu-plasminogen and Lys-plasminogen were prepared as described 
[34]. The kringle l-3 fragment of plasminogen was prepared from 
Glu-plasminogen as described by Sottrup-Jensen et al. [16]. Rabbit 
immunoglobulin raised against human asAP was from Dako, Glos- 
trup, Denmark. Urokinase was from Wakamoto, Tokyo, Japan. 
After gel filtration to remove 6-aminohexanoic acid, Lys-plasmino- 
gen (32 pM) was converted to plasmin by incubation with urokinase 
(0.1 pM) in 50 mM Tris-HCl, 0.1 M NaCl, 25% (v/v) glycerol, pH 7.7, 
for 120 min at 25°C. Its concentration of active plasmin (25 pM) was 
determined from rate measurements of hydrolysis of o-Val-Leu-Lys- 
pNA using K,,, = 150 nM and k, = 15.2 s-l [35,36]. 
aaAP was isolated from human plasma essentially as described by 
Wiman [37] with the modifications described by Bangert et al. [7]. The 
purified inhibitor was analysed by modified crossed immunoelectro- 
phoresis with Lys-plasminogen in the first dimention gel, which re- 
tards the migration of asAP with intact C-terminus, and anti-asAP in 
the second dimention gel [38]. No non-plasminogen-binding asAP 
was detected, the preparation apparently containing only C-terminally 
intact asAP. 
The concentration of asAP was determined by reactive site titration 
using a known amount of plasmin as described by Christensen and 
Clemmensen [30]. The amino acid sequence of the purified azAP and 
the amounts of Met’-asAP (38%) and Asni3-azAP (62%) were deter- 
mined as previously described [7]. 
2.3. Fluorescence spectra 
Fluorescence emission spectra of asAP, plasmin and mixtures 
thereof were recorded from 320 to 420 nm in 50 mM Tris-HCl, 0.1 
M NaCl, pH 7.4 at 25°C (this buffer was also used in all kinetic 
experiments) in a Perkin-Elmer LS-50 fluorometer. The excitation 
wavelength was 280 nm and the excitation and emission slits were 
each 5 nm. Inner filter effects were negligible. Various concentrations 
of plasmin (0.5-0.05 nM) and azAP (0.54l.05 FM) were used. After 
incubation for at least 5 min the spectra were recorded (flC]). Control 
spectra of inhibitor alone (401) and plasmin alone at various concen- 
trations (4E]), were used to calculate the relative fluorescence change 
according to Eq. 2: 
where flC], fiO] and flE] are the integrated intrinsic protein fluores- 
cence intensities at the actual concentrations. 
2.4. Stopped-jlow kinetic experiments 
Fast kinetic experiments were performed in a Hi-Tech Scientific PQI 
SF-53 spectrofluorometer equipped with a high-intensity xenon arc 
lamp. The excitation wavelength was 280 nm and slit width 5 nm. 
The light emitted from the reaction mixture passed through a WG 320 
filter before detection in the photomultiplier. The time course of in- 
trinsic fluorescence intensity changes of the fast reaction step of the 
inhibition reactions was recorded for an appropriate time (1, 2, or 10 
s) after mixing of equal concentrations of asAP and plasmin. The 
mixing time was less than 1 ms. The final concentrations were 1.1, 
0.55, 0.47, 0.22, and 0.11 pM. In each experiment 400 pairs of data 
were recorded, and sets of data from at least three experiments were 
averaged and analyzed with the Hi-Tech HS-1 Data Pro Software. 
The regression analysis used is based on the Gauss-Newton proce- 
dure. Background experiments showed each initial fluorescence inten- 
sity to be equal to the sum of that of plasmin and that of azAP, each 
obtained in the absence of the other compound. After recording l-10 
s of the reactions, control fluorescence measurements were made on 
the aged solution in the stopped-flow cell, the last one after 20 min. 
Such measurements showed no further changes of the fluorescence 
after the initial recording. Thus, only the fast step, and not the follow- 
ing slow step, gives rise to changes in the protein fluorescence when 
plasmin and azAP interact. 
2.5. Kinetics of inhibition progress 
To characterize the slow step and determine the rate (kz) of the 
expected rearrangement of the first complex to a more tightly bound 
final complex of asAP and plasmin, the residual activities of plasmin 
in equimolar azAP-plasmin reaction mixtures containing sufficient 
amounts of the proteins to leave measurable amounts of residual 
free plasmin after the formation of the first complex were determined 
over a long time range. The release of product was followed in a 
Perkin Elmer h17 spectrophotometer after manually mixing of plas- 
min (1.1 and 0.5 pM final concentration) with a solution of asAP (1.1 
and 0.55 pM final concentration) and H-o-Val-Leu-Lys-pNA (final 
concentration 1.24 mM). The rate corresponding to the residual plas- 
min activity was determined as a function of time from the slope (the 
first time derivative) of the recorded curve, which was calculated using 
the PECSS software of the Perkin-Elmer spectrophotometer. 
In such experiments an exponential decrease in plasmin activity 
corresponding to a slow first order reaction step occurring after the 
fast initial equilibration of the first step was seen, as has also been 
previously reported [30]. The zero time value of the fitted exponential 
equation is the point that corresponds to the initial value of the 
second reaction step for a theoretical immidiate equilibration of the 
first step. It was used to calculate K 1, assuming full equilibration 
between substrate, enzyme and inhibitor (with respect to the first 
step) during that part of the slow step on which the fitted exponentials 
were based. 
3. Results 
3.1. Fluorescence spectra 
Fluorescence emission spectra were obtained for azAP, 
plasmin and the azAP-plasmin complex (Fig. 1). Emission 
maxima were all at 340 nm. Interestingly, the fluorescence 
intensity of the sum of the uncomplexed components (trace 
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Fig. 1. Fluorescence spectra of plasmin and aa-antiplasmin. Fluores- 
cence spectra were recorded from 320 to 420 nm in 50 mM Tris- 
HCl, 0.1 M NaCl, pH 7.4 at 25°C after excitation at 280 nm. 
(A) Sum of spectrum of plasmin (50 nM), and spectrum of asAP 
(50 nM). (B) Spectrum of complex of plasmin and azAP (50 nM). 
(C) Difference of A and B. 
60 
time (s) 
Fig. 2. Typical time courses of the stopped-flow fluorescence signal 
resulting from the inhibition of plasmin by azAP. Plasmin and 
asAP were mixed and the fluorescence followed for 10 s. The aver- 
age of 3 traces is shown.The curve is that resulting from the best fit 
to the data of the equation that describes second order kinetics (Eq. 
3). Series of such experiments were performed at various concentra- 
tions of enzyme and inhibitor in the presence and absence of t-AM- 
CHA (O-10 mM). 
A) exceeded the fluorescence of the complex (trace B), show- 
ing a substantial fluorescence intensity decrease in the com- 
plex (13 + 1%) and no further changes after incubation for 
periods much longer than the 5 min used here. This allows 
direct monitoring of the first step of the azAP reaction with 
plasmin in the absence of a plasmin substrate. 
3.2. Stopped-flow kinetics 
The kinetics of the reactions of azAP with plasmin was 
investigated by mixing series of equimolar concentrations of 
the two proteins using the stopped-flow technique. A typical 
stopped-flow trace of the resulting decrease in fluorescence 
intensities is shown in Fig. 2. Also, the fitted curve corre- 
sponding to Eq. 3, which describes second order reaction ki- 
netics at equal concentrations of the two reactants, is illu- 
strated. 
M(t) = Wm) (I-- l  + ;&I) 
AF(t) is the relative fluorescence change at time t, AF(m) is 
the limit value for t+ m corresponding to completion of the 
current reaction step, and E,, is the concentration of plasmin 
equal to that of azAP. kl is the observed second order rate 
constant. The fluorescence change solely accompanies the for- 
mation of a first association complex of azAP and plasmin, 
no further changes being seen when measurements were made 
in the stopped-flow fluorimeter at reaction times much greater 
than that corresponding to 5-6 (concentration dependent) 
half-times of the first association reaction, i.e. after its com- 
pletion. There was reasonable internal agreement between the 
values obtained for kl, 2.2X lo7 M-’ s-l being the mean 
value from all the measured data in the absence of t-AM- 
CHA. The presence of t-AMCHA, however, affects the ob- 
served rate constant significantly (Fig. 3). The concentration 
dependence of this effect of t-AMCHA results in a final 20- 
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fold decrease of the rate constant in the concentration range 
O-l mM. These concentrations are so low that active site 
interaction (Ki = 16 mM [39]) is negligible; the effect, however, 
corresponds with interactions of t-AMCHA at the LBS of 
plasmin. The curve shown in Fig. 3 is obtained from a fit to 
Eq. 4: 
Ak(Z) = A + B/(1 + K&I) (4) 
where Ak(I) is the difference in the observed rate constant in 
the absence and of t-AMCHA at concentration I; 
kl(O)-kl(Z); A is a constant: the initial decrease correspond- 
ing to saturation of the LBS of kringle 1; B is another con- 
stant : the maximal value of the further decrease obtained as a 
function of the degree of saturation of a LBS with dissocia- 
tion constant, KLSS. The best fit resulted in KLSS = 34 nM 
(accuracy 15%), a B value of 0.1 X kl(O), where 
kl(0) = 2.2 X IO7 M-l s-l is the value obtained in the absence 
of t-AMCHA, and an A value of 0.47X kl(0). This clearly 
indicates an important interaction with the LBS of kringle 4 
(KLBS = 36 pM of kringle 4 of Lys-plasminogen [40]) leading 
to a IO-fold rate loss, whereas saturation of kringle 1, 
KLSS = 0.42 uM [11,40,41] results in only a 2-fold decrease 
in the rate. 
3.3. Inhibition progress kinetics 
Time course experiments measuring residual plasmin activ- 
ity after completion of its fast association reaction with azAP 
to obtain the equilibrium constant of the first complex, and 
the rate of the slow reaction, clearly confirmed the pattern 
originally discussed for the reaction of human plasmin and 
azAP [30]. To characterize the slow step the residual plasmin 
catalysed rate of substrate hydrolysis was measured in the 
L 
0 200 400 600 800 1000 
t-AMCHA (PM) 
Fig. 3. Dependence of the observed second order rate constant on 
the concentration of t-AMCHA. The decrease in the second order 
rate constant from 2.2~ lo7 M-‘s-l in the absence of t-AMCHA 
to a limit value of 1.1 x lo6 M-r s-l in the presence of LBS-satu- 
rating concentrations of t-AMCHA is illustrated. The curve shown 
is that resulting from the best fit to the data of Eq. 4 (see text), 
that describes an initial decrease, A (fitted value 0.47 Xkl(O)), best 
explained as an effect of saturation of the LBS of kringle 1, fol- 
lowed by a decrease, B (fitted value 0.1 X kl(0)) that becomes fully 
effective when a LBS with &a (fitted value 34 PM) is saturated 
with t-AMCHA, best explained as an effect of saturation of the 
LBS of kringle 4. 
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presence of substrate and azAP. The time dependence of the 
rates was obtained as the first time derivative of recorded (10 
points per s) curves (not shown). The results showed single 
exponential decays of the rates with a first order rate constant 
of the slow step, kz = 2 x 10e3 s-l (accuracy approx. 5%) and 
no effects of t-AMCHA on the slow step were observed. This 
is in agreement with previous observations [30]. The resultant 
value of Kl in the absence of t-AMCHA was determined to be 
(1 f 0.3) x 10-l’ M. 
As is known from previous reports on the reaction of hu- 
man plasmin with azAP the final complex formed is so tightly 
bound that the reaction may be considered irreversible. Only 
under extreme experimental conditions, e.g. in the presence of 
az-macroglobulin, which actually forms a covalent isopeptide 
bonded complex with plasmin [42] may dissociation of the 
final plasmin-a2-antiplasmin complex be detected. This ‘irre- 
versibility’ is thus due to an extremely slow reverse reaction in 
the second reaction step (k-2). 
4. Discussion 
In human plasminogen the kringle 1-3 fragment does not 
bind intact fibrin [16,43,44], but may participate in the en- 
hanced binding during plasmin-catalysed fibrin degradation, 
when C-terminal lysine residues, that serve as ligands for such 
binding, are formed [11,45]. The possibility of a more promi- 
nent role of the LBSs of kringles 4 and 5 rather than of the 
kringle I-LBS as regulatory domains in the human system has 
recently received attention [l 1,12,15,33,46,47]. 
A large change in relative fluorescence is seen when plasmin 
and CQAP associates (Fig. 1). Stopped-flow fluorescence meas- 
urements showed that this change occurs in the fast step of 
the reaction (Fig. 2). This allowed for determinations of val- 
ues of the association rate constant, kl, under conditions 
unaffected by the presence of substrates. The stopped-flow 
mixing technique allows measurement after just 1 ms, and 
thus not when most of the fast reaction has taken place as 
happens when one is using manual mixing [9,28-311. The as- 
sociation rate shows up to 20-fold reduction in the presence of 
t-AMCHA 1 mM (Fig. 3). The concentration dependence 
shows that the rate reduction is only 2-fold in the range 5- 
25 uM, when the LBS of kringle 1 is saturated, whereas sat- 
urating the LBS of kringle 4 with t-AMCHA results in a 
further lo-fold reduction. The effect of t-AMCHA on the 
reaction allows us to estimate the dissociation constant KLSS 
(34 FM) for the interaction between the LBS and t-AMCHA. 
This range is consistent with a binding site for t-AMCHA in 
Lys-plasminogen with Kd = 36 uM described by Markus et al. 
[40], originally located at kringle 4 [16]. Since kringle 5 alone 
as in miniplasmin reveals no kinetic effects on the inhibition 
by azAP [28], and since the active site is inhibited only at very 
high concentrations of t-AMCHA (Ki = 16 mM [39]), we con- 
clude that kringle 4 is of importance in the regulation of the 
inhibition of plasmin by aZAP. The kringle l-3 fragment of 
plasminogen indeed binds CX~AP as is known from the affinity 
purification of azAP [3,48], and effects of lysine-analog li- 
gands on the reaction of azAP with plasmin have in general 
been attributed to the LBS of kringle 1 [48]. This generally 
accepted belief is not supported. Our findings suitably explain 
that not only the C-terminal lysine residue, but also Lys-475 
[lo] of human a2AP seem important in the reaction, if kringle 
4 as well as kringle 1 is involved in the regulation of the 
azAP-plasmin reaction. The involvement of two LBS parallels 
the finding that the LBS of kringles 4 and 5 are allosterically 
involved in the ligand-induced conformational change of Glu- 
plasminogen that governs its rate of activation [12]. 
Plasmin reacts with azAP in a manner in which a first 
association complex, the formation of which is dependent 
on LBS-interactions, is converted into a much tighter second 
complex in a slow reaction step. The dissociation constant for 
the first association complex, KI = 1 x lo-” M, and the rate 
constant for tightening of the complex, kz = 2 X 10e3 s-l, were 
obtained. These values are consistent with results of Christen- 
sen and Clemmensen [13,30], Christensen et al. [28] and Long- 
staff and Gaffney [31]. 
Recently, Longstaff and Gaffney [31] argued that lysine 
analogs such as t-AMCHA should not act by blocking a 
second site for the inhibitor on the enzyme. However, in 
our experiments (Fig. 3) the active site inhibition (KD = 16 
mM) cannot account for the effect on kI, which must be 
explained in terms of binding of t-AMCHA to a secondary 
site (LBS). This model is also supported by the work of Su- 
giyama et al. [lo] who analyzed the effect of C-terminal pep- 
tides from azAP on the reaction with plasmin and showed the 
importance of the C-terminus of azAP for fast inhibition (kI) 
of plasmin. It should be noted, however, that blocking of the 
LBS merely slows the reaction down; it is not stopped and is 
still rather fast with kl(Z) = 1.1 x lo6 M-’ s-l at 1 mM con- 
centration of t-AMCHA. 
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